免疫亲和富集细胞外囊泡蛋白质组学用于高级别浆液性卵巢癌:UKOPS巢式病例对照分析
该研究基于UKOPS巢式病例对照队列中243对EDTA血浆与血清样本,对细胞外囊泡(EV)亚群进行免疫亲和富集蛋白质组学分析,评估血浆与血清的可互换性及EV蛋白特征对卵巢癌的诊断价值。结果显示血浆EV蛋白质组深度更高,两基质间蛋白强度高度一致(r=0.86,p<0.001);EV增强的CA-125模型区分HGSOC与非癌的AUROC在血浆为0.97、血清为0.96,血浆灵敏度99%(95%CI 89-100)、特异度85%(95%CI 68-91),优于单用CA-125。
要点
- 血浆与血清EV蛋白质组特征高度一致(r=0.86),支持两者可互换使用。
- EV增强CA-125模型在血浆中区分HGSOC与非癌的AUROC达0.97。
- EV增强模型血浆灵敏度99%、特异度85%,优于单用CA-125。
核心结论
- 表面表位靶向的EV亚群富集可实现HGSOC特异性蛋白质组分析,血浆与血清标志物特征高度一致。
- EV增强的CA-125模型优于单用CA-125,反复出现的EV蛋白反映黏蛋白介导的免疫逃逸和代谢重编程。
研究设计与样本
- UKOPS巢式病例对照队列,纳入243对EDTA血浆与血清样本,含对照、良性、交界性和HGSOC。
- 对EV亚群进行免疫亲和富集蛋白质组学分析,评估蛋白质组深度、血浆-血清一致性和机器学习诊断性能。
主要发现
- 血浆EV亚群蛋白质组深度高于血清,分别鉴定6439和5451个蛋白组,50%检出率下分别检测到2838和840个蛋白。
- 蛋白强度在两种基质间高度一致(r=0.86,p<0.001),且在各疾病组和癌症分期中维持。
- 区分HGSOC与非癌时,EV增强CA-125模型血浆AUROC为0.97、血清为0.96。
- 血浆EV增强模型灵敏度99%(95%CI 89-100)、特异度85%(95%CI 68-91),单用CA-125为灵敏度96%(95%CI 82-100)、特异度65%(95%CI 15-73)。
临床怎么用
- 血浆和血清均可用于EV蛋白质组学检测,便于临床和生物样本库灵活选择样本类型。
- EV增强CA-125模型可提高HGSOC检测的特异度,减少假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether plasma and serum extracellular vesicles (EV) are interchangeable for immunoaffinity-enriched proteomic profiling in high-grade serous ovarian cancer (HGSOC), and whether an EV protein signature improves diagnostic performance beyond CA-125 for detecting ovarian cancer. METHODS: We performed immunoaffinity-enriched proteomic profiling of EV subpopulations from 243 paired EDTA plasma and serum samples in a nested case-control cohort from the UK Ovarian Cancer Population Study (controls, benign, borderline, and HGSOC). Analyses assessed proteomic depth, plasma-serum concordance, and diagnostic performance using machine learning. RESULTS: Plasma-derived EV subpopulations showed greater proteomic depth than serum, with 6439 versus 5451 protein groups identified and 2838 versus 840 proteins detected at 50% prevalence. Protein intensities were highly concordant between matrices (r = 0.86, p < 0.001), maintained across disease groups and cancer stages. For distinguishing HGSOC from non-cancers, an EV-augmented CA-125 model achieved an AUROC of 0.97 in plasma and 0.96 in serum, improving plasma sensitivity to 99% (95% CI 89-100) and specificity to 85% (95% CI 68-91) versus 96% (95% CI 82-100) sensitivity and 65% (95% CI 15-73) specificity for CA-125 alone, with similarly high discrimination in serum. CONCLUSIONS: Surface epitope-targeted EV subpopulation enrichment yields specific proteomic profiling of HGSOC with highly concordant biomarker signatures across plasma and serum, supporting their interchangeable use in clinical and biobank settings. The EV-augmented CA-125 model outperformed CA-125 alone, with recurrent EV proteins reflecting mucin-mediated immune evasion, and metabolic reprogramming, underscoring the translational potential of this approach for blood-based ovarian cancer detection.
引用
- Salomon C, Lai A, Guanzon D, et al. Immunoaffinity-enriched extracellular vesicle proteomics for high-grade serous ovarian cancer - A UKOPS nested case-control analysis. Gynecol Oncol. 2026. PMID: 42880206. doi:10.1016/j.ygyno.2026.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。